Predictive Significance of Thymidylate Synthase Expression in Non-small Cell Lung Cancer
Language English Country Greece Media print
Document type Journal Article
PubMed
29187479
DOI
10.21873/anticanres.12161
PII: 37/12/6953
Knihovny.cz E-resources
- Keywords
- NSCLC, Thymidylate synthase, prognosis,
- MeSH
- Chemotherapy, Adjuvant MeSH
- Kaplan-Meier Estimate MeSH
- Middle Aged MeSH
- Humans MeSH
- Biomarkers, Tumor genetics MeSH
- Lung Neoplasms drug therapy genetics surgery MeSH
- Carcinoma, Non-Small-Cell Lung drug therapy genetics surgery MeSH
- Prognosis MeSH
- Antineoplastic Combined Chemotherapy Protocols MeSH
- Gene Expression Regulation, Neoplastic * MeSH
- Aged MeSH
- Thymidylate Synthase genetics MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Biomarkers, Tumor MeSH
- Thymidylate Synthase MeSH
BACKGROUND/AIM: To date, many studies have suggested that thymidylate synthase (TS) could be used as a prognostic and predictive marker in non-small cell lung cancer (NSCLC) patients. However, results have been contradictory. The aim of this study was to evaluate TS mRNA levels in tumor tissue of NSCLC patients who underwent complete surgical resection and to analyze its prognostic and predictive potential. MATERIALS AND METHODS: The study group consisted of 64 patients who underwent curative lung resection. Paired lung tissue samples were taken directly from the tumor tissue and from adjacent, histologically cancer-free lung tissue. The quantitative estimation of TS expression was performed by reverse transcription real-time polymerase chain reaction (RT-qPCR). The relationship between TS expression level and disease-free interval (DFI) and overall survival (OS) was analyzed. RESULTS: There was significantly higher TS expression in NSCLC tumor tissue comparing to normal lung tissue. In the group of patients who received adjuvant chemotherapy based on platinum derivatives in combination with paclitaxel or gemcitabine, we found shorter DFI (p=0.0473) and OS (p=0.0053) in those with high expression of TS. CONCLUSION: Our results demonstrated the relationship of high tumor tissue TS levels to adverse prognosis in patients undergoing adjuvant chemotherapy. TS is a non-specific tumor marker with respect to NSCLC, therefore we think that its best use would be as a member of the panel of predictors of adjuvant treatment efficacy.
Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Department of Biology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Department of Pneumology and Phthisiology University Hospital in Pilsen Pilsen Czech Republic
Department of Surgery University Hospital in Pilsen Pilsen Czech Republic
Immunoanalytic Laboratory University Hospital in Pilsen Pilsen Czech Republic
References provided by Crossref.org
